Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (also referenced as Newcelx Ltd. in metadata) covers the month of November 2024, with a filing date of November 6, 2024. The registrant is a foreign private issuer headquartered in Zurich, Switzerland. The primary purpose of this report is to announce an Extraordinary Shareholders' Meeting scheduled for November 8, 2024.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this document. The filing focuses solely on the administrative details of the upcoming shareholder vote.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding operational performance in this filing. The document incorporates by reference the Notice of Meeting and Proxy Card for the Extraordinary Shareholders' Meeting. Only shareholders of record as of the close of business on October 17, 2024, are entitled to vote at the meeting.
Key Facts for Investor Verification
- Meeting Date: The Extraordinary Shareholders' Meeting is set for November 8, 2024.
- Record Date: Shareholders must have held common shares as of October 17, 2024, to be eligible to vote.
- Document Reference: The Notice of Meeting and Proxy Card are attached as Exhibit 99.1.
- Registration Impact: This report is incorporated by reference into the company's active Form F-3 Registration Statements.
- Financial Data: No financial metrics are included in this specific filing.